Mark

“It was good to see the enrollment for Alpha 3 post the interim data. Could you give us a breakdown of enrollment cadence across academic versus community sites?”

“I recognize the importance of FSD and that FSD can help to drive vehicle sales. And nice to see some of the improvements in the FSD technology more recently with version 14.”

“So, from your conversations with regulators, do you expect that additional mitigation strategies would be necessary beyond what you've already implemented in magnitude 2 in order to resolve the magnitude study clinical hold.”

“Can you talk about what drove the decision to include the interim PFS analysis for Harmony 3 for the squamous cohort and also frame expectations for both the initial data in the second quarter and also the potential final PFS analysis in interim OS in the second half?”

“A couple questions on the upcoming Harmony EGFR data set. So I think everyone's going to be focused on sort of the subgroup data to confirm if the Kezo's prior data generated in China translates to Western regions.”